<DOC>
	<DOCNO>NCT01871532</DOCNO>
	<brief_summary>This prospective , multicenter , open-label , comparative parallel-group study ovulation induction evaluate tailor Recombinant follicle stimulate hormone ( FSH ) treatment use Gonal-f® prefilled pen World Health Organization ( WHO ) Type 2 anovulatory subject previously fail conceive clomifene treatment .</brief_summary>
	<brief_title>Low-dose Gonal-f® Ovulation Induction</brief_title>
	<detailed_description>Subjects enter screen period one month randomize Baseline Visit , occur Day 1 subject 's menstrual cycle . Each subject receive 4 week treatment Gonal-f® . If adequate follicular development ( assessed transvaginal ultrasound ) achieve , subject proceed administration human chorionic gonadotropin ( hCG ) within 24-48hrs last Gonal-f® injection ( accord standard site practice ) . Following administration hCG , subject attempt become pregnant via intercourse intrauterine insemination . The method conception determine subject 's requirement standard practice clinic site . All subject follow appropriately confirmation biochemical pregnancy ( hCG + minimum 14 day ) clinical pregnancy ( hCG + minimum 42 day , subject positive biochemical pregnancy test ) .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Subjects eligible ovulation induction treatment , monofollicular development desire treatment outcome dose schedule outline protocol deem appropriate Premenopausal female subject , age 18 37 year inclusive Subjects desirous pregnancy/willing conceive Subjects infertile due chronic anovulation demonstrate cycle duration great 35 day . Subjects treat clomifene citrate therapy , accord standard site practice , fail ovulate and/or conceive Subjects follicle stimulate hormone ( FSH ) prolactin ( PRL ) serum value within normal range early follicular phase Subjects overall total antral follicle count great 10 ( follicle size great equal 2 millimeter [ mm ] le 11 mm ) ( , total ovary ) Subjects least one patent tube , document recent ( within 2 year treatment assignment ) hysterosalpingography ( HSG ) hysterosalpingo contrast sonography ( HyCoSy ) Subjects normal uterine cavity , document recent ( within 2 year treatment assignment ) hysteroscopy , HSG ultrasound scan Subjects body mass index ( BMI ) great 20 less equal 32 kilogram per square meter ( kg/m^2 ) ( BMI equal body weight [ kilogram { kg } ] divide Height * Height [ square meter { m^2 } ] ) Subjects negative cervical Papanicolaou ( PAP ) test conduct accord national guideline and/or standard site practice Male partner female subject sperm compatible nonassisted fertilization availability donor sperm , confirm Investigator Subjects willing able comply protocol requirement provide write , informed consent Subjects history hypersensitivity investigational medicinal product ( IMP ) ( active substance follitropin alpha , FSH , excipients Gonalf® ) drug use trial ( , Ovitrelle ) Subjects ovarian enlargement ovarian cyst unrelated Polycystic Ovary Syndrome ( PCOS ) , unknown origin ultrasound Subjects evidence diminish ovarian reserve ( cycle length le 26 day ; FSH upper limit local serum FSH value , total antral follicle count [ AFC ] ovaries less 10 ) Subjects uterine pathology/abnormalities , opinion Investigator could impair pregnancy evolution Subjects undergone three previous miscarriage Subjects previous extrauterine pregnancy Pregnant lactate female subject Subjects abnormal gynecological bleed unknown etiology . Subjects previous history severe ovarian hyper stimulation syndrome ( OHSS ) ( clomifene treatment ) Subjects evidence current previous pelvic inflammatory disease treatment assignment Subjects tumor hypothalamus pituitary gland Subjects ovarian , uterine mammary carcinoma Subjects treat clomifene citrate gonadotropin within 1 month screen evaluation Subjects medical condition , opinion Investigator , would prevent effective response , primary ovarian failure , malformation reproductive organ incompatible pregnancy Subjects medical condition , opinion Investigator , may interfere absorption , distribution , metabolism excretion drug Subjects clinically significant systemic disease ( example , insulindependent diabetes ) contraindication pregnant and/or carry pregnancy term An active substance abuser Known infection human immunodeficiency virus ( HIV ) , Hepatitis B C virus trial subject male partner Subjects currently participate another clinical trial Subjects unable give write informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Monofollicular Development</keyword>
	<keyword>Gonal-f®</keyword>
	<keyword>Recombinant Follicle Stimulating Hormone</keyword>
	<keyword>Ovarian hyperstimulation syndrome ( OHSS )</keyword>
</DOC>